(P036) Causes of Mortality Among Cancer Patients

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Cancer patients with the highest risk of index and nonindex cancer death and medical comorbidity death are identified; certain patient groups may be targeted with interventions.

Nicholas G. Zaorsky, MD, Thomas M. Churilla, MD, Brian Egleston, PhD, Elizabeth Handorf, PhD, Eric M. Horwitz, MD, Joshua E. Meyer, MD; Fox Chase Cancer Center

BACKGROUND: Causes of mortality among cancer patients are not well characterized.

PURPOSE: To characterize the causes of death among cancer patients after diagnosis (1) as a function of calendar year and (2) compared with the general population.

METHODS: Surveillance, Epidemiology, and End Results Stat 8.2.1 was used to create a rate session, from 1973 to 2012. Data were characterized by raw count and percentages. Death was characterized as due to index cancer, non–index cancer, and noncancer medical comorbidity. Further, data were characterized using standardized incidence ratio (SIR) vs time after diagnosis (time binned), which provides the relative risk of death as compared with patients who do not have cancer in the US, from 2007 to 2012. At least 1,000 person-years at risk (PYARs) were necessary for analysis.

RESULTS: For the calendar year session, there were 1,857,363 mortalities. The greatest decrease in index cancer death (generally from > 60% to < 30% of patients) was among patients with cancer of the larynx, gallbladder, stomach, bladder, endometrium, breast, and testis; melanoma; non-Hodgkin lymphoma (NHL); and Hodgkin lymphoma. Index cancer deaths (typically > 40%) have been stable or rising among patients with cancer of the liver, pancreas, lung and bronchus, soft tissue, and nasopharynx. Noncancer causes of death are highest (vs index or nonindex cancer) in patients with cancers of the rectum, bladder, kidney, endometrium, breast, prostate, and testis. The highest SIRs (range: 2–200) were typically within the first year after diagnosis of any cancer. The highest SIRs were from other infections (eg, SIR > 100 for lymphomas), chronic liver disease (SIRs > 20 for cervix, lung, and oral cavity cancers), and suicide (SIR > 15 for testis, lung, oral cavity, and NHL), followed by heart disease, diabetes, and accidents.

CONCLUSION: Cancer patients with the highest risk of index and nonindex cancer death and medical comorbidity death are identified; certain patient groups may be targeted with interventions.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content